The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy
| Autor: | Douglas P. Slakey, L. Lee Hamm, Sandy Florman, Sharmila Devidoss, April Zarifian, Rubin Zhang, Anil Paramesh, Vecihi Batuman, Vivian Fonseca, Mary Killackey |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Transplantation Conditioning Basiliximab medicine.medical_treatment Recombinant Fusion Proteins Urology Pancreas transplantation Mycophenolate Organ transplantation Maintenance therapy parasitic diseases medicine Humans Survivors Kidney transplantation Retrospective Studies Transplantation business.industry Graft Survival Antibodies Monoclonal Middle Aged medicine.disease Kidney Transplantation Tacrolimus Surgery Female Pancreas Transplantation business Immunosuppressive Agents medicine.drug |
| Zdroj: | Clinical transplantation. 21(5) |
| ISSN: | 0902-0063 |
| Popis: | Interleukin-2 receptor (IL2R) antibody has emerged as an attractive induction therapy for organ transplant. However, the long-term outcome of basiliximab induction in simultaneous pancreas and kidney (SPK) transplant remains speculative. We retrospectively analyzed the long-term survivals of 91 consecutive SPK recipients with basiliximab as induction, combination of steroid, tacrolimus (TAC) and mycophenolate acid (MFA)--either mycophenolate mofetil (MMF) or sodium mycophenolate (myfortic) as maintenance. At one, three, five, and seven-yr, the actual patient survival rate were 91.2%, 90.3%, 88.1%, and 88.2%, respectively; kidney graft survivals were 90.1%, 84.7%, 78.6%, and 70.6%, respectively; and pancreas graft survivals were 86.8%, 80.6%, 71.4%, and 58.8% respectively. There was a low incidence of rejection and CMV infection. Basiliximab induction with TAC, MFA, and steroid maintenance therapy can provide excellent long-term outcome for SPK recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|